Singh Vishal, Yeoh Beng San, Vijay-Kumar Matam
Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA 16802, USA.
Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA 16802, USA; Department of Medicine, The Pennsylvania State University Medical Center, Hershey, PA 17033, USA.
Curr Opin Pharmacol. 2016 Apr;27:8-12. doi: 10.1016/j.coph.2016.01.002. Epub 2016 Jan 30.
Over the last two decades, our understanding of gut microbiotal composition and its association with intra-intestinal and extra-intestinal diseases including risk factors of cardiovascular disease (CVD) namely metabolic syndrome and atherosclerosis, have been increased exponentially. A pertinent question which often arises in researchers' community is on how to manipulate the gut microbial ecology to 'cure' the cardiovascular risk factors. Accordingly, in this review we summarized the potential strategies, based on our current knowledge on gut microbiota in modulating CVD, how gut microbiota can be therapeutically exploited by targeting their metabolic activity to alleviate the risk factors of CVD.
在过去二十年中，我们对肠道微生物群组成及其与肠道内外疾病（包括心血管疾病（CVD）的危险因素，即代谢综合征和动脉粥样硬化）之间关联的理解呈指数级增长。研究人员群体中经常出现的一个相关问题是如何操纵肠道微生物生态以“治愈”心血管危险因素。因此，在本综述中，我们基于目前对肠道微生物群在调节心血管疾病方面的认识，总结了潜在策略，即如何通过靶向肠道微生物群的代谢活性来治疗性地利用它们，以减轻心血管疾病的危险因素。
